Want to see SLSN full AI Analyst Report?
Top Page
Solesence
(NASDAQ:SLSN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.93
▼(-1.49% Downside)
Action:Reiterated
Date:08/20/26
The score is held down primarily by weakening TTM financial performance (return to losses and negative/free cash flow) and a weak technical trend (trading below key longer-term moving averages). Partially offsetting these, management’s earnings-call guidance points to a stronger second half supported by a higher order book, though restatement/control issues and the lack of profitability keep the overall score below average.
Positive Factors
Growing Order Book
The approximately 8.2% increase in shipped and on-hand orders provides better forward visibility. If converted into revenue, the larger order base can support recovery, capacity utilization, and management’s expectation of stronger second-half performance.
Negative Factors
Revenue and Profitability Deterioration
The reversal from prior growth and profitability indicates weaker demand conversion and execution risk. Sustained revenue contraction can reduce operating leverage, while renewed losses limit internally generated funding for innovation, capacity, and commercial expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Growing Order Book
The approximately 8.2% increase in shipped and on-hand orders provides better forward visibility. If converted into revenue, the larger order base can support recovery, capacity utilization, and management’s expectation of stronger second-half performance.
Read all positive factors
Solesence (SLSN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$66.09M
Dividend YieldN/A
Average Volume (3M)50.43K
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth-14.05%
EPS Growth-135.74%
CountryUS
Employees115
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.03
Shares Outstanding70,647,040
10 Day Avg. Volume39,901
30 Day Avg. Volume50,427
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)6.38
Price to Sales (P/S)1.81
P/FCF Ratio-10.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Solesence Business Overview & Revenue Model
Company Description
Solesence, Inc., formerly known as Nanophase Technologies Corporation, specializes in the development and production of clean-label, inclusive, and mineral-based skincare and cosmetic products. The company collaborates with a diverse range of part...
How the Company Makes Money
null...
Solesence Earnings Call Summary
Earnings Call Date:Aug 19, 2026
(Q2-2026)
| Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Neutral
The call presents a mixed picture: materially weaker reported Q2 revenue and profitability and a significant accounting remediation (inventory costing restatements) are clear negatives that expose historical control weaknesses and distorted year-over-year comparatives. Offsetting this, management highlights tangible operational improvements (labor efficiency, OEE), a growing order book (shipped and on-hand orders up ≈8.2% year-over-year), new product launches targeting sizable addressable markets, and confident guidance for a stronger second half and full-year outperformance versus 2025. Management has committed to remediation actions and control enhancements. Overall, positives around backlog growth, product pipeline, and remediation efforts balance the near-term financial and control challenges.Positive Updates
Order Book Growth and Positive Full-Year Outlook
Shipped and on-hand orders as of August 17 totaled $64.9 million, up from $60.0 million in the same period a year ago (≈+8.2%). Management now expects to outperform 2025 on a full-year revenue basis and projects the second half of 2026 to generate approximately $35 million in revenue — the strongest second-half performance in company history.
Negative Updates
Significant Year-Over-Year Revenue Decline
Second quarter revenue was $15.3 million versus $20.4 million in Q2 2025, a decline of approximately 25%. The prior-year quarter benefited from a major new product launch and pipeline fill, and revenue for that specific product was lower in Q2 2026.
Read all updates
Q2-2026 Updates
Positive
Negative
Order Book Growth and Positive Full-Year Outlook
Shipped and on-hand orders as of August 17 totaled $64.9 million, up from $60.0 million in the same period a year ago (≈+8.2%). Management now expects to outperform 2025 on a full-year revenue basis and projects the second half of 2026 to generate approximately $35 million in revenue — the strongest second-half performance in company history.
Read all positive updates
Company Guidance
The company guided that it now expects to outperform 2025 on a full‑year revenue basis and to deliver sequential improvement in Q3 revenue and profitability, forecasting the second half of 2026 to generate approximately $35.0 million (its strongest second half ever) and citing $64.9 million in shipped and on‑hand orders as of August 17 (up from $60.0 million a year earlier); Q2 results included $15.3 million of revenue versus $20.4 million in Q2 2025 (about 25% lower), a 31% gross margin (restated 32% in Q2 2025), a Q2 net loss of $0.158 million versus prior‑year net income of $3.2 million, and adjusted EBITDA of $0.523 million versus $3.7 million prior, with one‑time REFY items reducing net income by ~$0.938 million and an ERC benefit of ~$1.4 million in Q2 2025 noted—management also reiterated expectations for double‑digit growth and improvements in labor/OEE efficiency while targeting continued operational control improvements.Solesence Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
62
Positive
Cash Flow
39
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.37M | 62.06M | 52.35M | 37.30M | 37.32M | 29.48M |
| Gross Profit | 14.87M | 16.03M | 16.19M | 7.83M | 8.36M | 8.69M |
| EBITDA | 91.00K | 3.69M | 6.06M | -2.80M | -1.69M | 3.96M |
| Net Income | -1.88M | 1.79M | 4.24M | -4.39M | -2.62M | 2.32M |
Balance Sheet | ||||||
| Total Assets | 46.44M | 50.05M | 50.00M | 32.88M | 33.56M | 28.39M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 1.29M | 1.41M | 1.72M | 2.19M | 657.00K |
| Total Debt | 22.70M | 24.32M | 15.30M | 21.26M | 18.11M | 14.75M |
| Total Liabilities | 33.28M | 32.42M | 35.06M | 30.98M | 27.91M | 20.93M |
| Stockholders Equity | 13.15M | 17.63M | 14.95M | 1.90M | 5.65M | 7.46M |
Cash Flow | ||||||
| Free Cash Flow | -1.81M | -10.71M | -2.59M | -3.06M | -4.47M | 447.00K |
| Operating Cash Flow | 1.02M | -8.57M | 1.97M | -2.01M | -1.65M | 2.32M |
| Investing Cash Flow | -1.86M | -2.14M | -4.56M | -1.05M | -2.82M | -1.87M |
| Financing Cash Flow | -2.21M | 10.59M | 2.27M | 2.59M | 6.00M | -747.00K |
Solesence Technical Analysis
Negative
0.94
Price Trends
0.93
Positive
1.10
Negative
1.33
Negative
Market Momentum
<0.01
Positive
48.57
Neutral
47.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLSN, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 0.98, above the 50-day MA of 0.93, and below the 200-day MA of 1.33, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.57 is Neutral, neither overbought nor oversold. The STOCH value of 47.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLSN.
Solesence Risk Analysis
Solesence disclosed 27 risk factors in its most recent earnings report. Solesence reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Solesence Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
58 Neutral | $1.33B | -14.33 | -6.27% | 2.17% | -7.00% | -246.78% | |
57 Neutral | $673.14M | -1.62 | -48.24% | ― | -2.08% | -23.88% | |
51 Neutral | $236.08M | -1.09 | -29.42% | 4.72% | -15.44% | -319.79% | |
47 Neutral | $66.09M | -36.82 | -11.58% | ― | -14.05% | -135.74% | |
47 Neutral | $84.60M | -3.04 | -47.84% | ― | -6.45% | -44.06% |
* Consumer Defensive Sector Average
SLSN
Solesence
0.95
-2.64
-73.57%
HELE
Helen Of Troy
29.14
4.08
16.28%
NUS
Nu Skin
4.84
-7.02
-59.17%
EPC
Edgewell Personal Care
28.65
5.82
25.49%
SKIN
Beauty Health
0.69
-1.36
-66.59%
Solesence Corporate Events
Business Operations and StrategyLegal Proceedings
Solesence Settles Dispute, Launches New SPF Collaboration
Positive
Jul 10, 2026
On July 6, 2026, Solésence, LLC entered into a Settlement Agreement with Refy Beauty Ltd to resolve disputes over certain consumer care products previously sold to Refy. Under the agreement, Solésence will pay Refy the British Pound Ster...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.